THALIDOMIDE FOR TREATMENT OF ORAL/ESOPHAGEAL APHTHYOUS ULCERS AND HIV VIREMIA

沙利度胺用于治疗口腔/食管口疮溃疡和 HIV 病毒血症

• 批准号: 6117759
• 负责人: JOSEPH WHEAT
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117759
• 关键词: HIV infections; aphthous stomatitis; clinical research; drug screening /evaluation; esophagus disorder; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; oral pharyngeal disorder; placebos; thalidomide

This study will employ a multi-center, phase II/III, double-blind randomized, placebo-controlled design. Patients with HIV infection and oral and/or esophageal aphthous ulcers of more than two weeks duration will be entered. Patients will be randomized to receive a 4 week course of either 200 mg thalidomide or placebo orally once daily.

本研究将采用多中心、II/III期、双盲 随机、安慰剂对照设计。 艾滋病毒感染者和 口腔和/或食管阿弗他溃疡持续时间超过2周 将被输入。 患者将随机接受4周疗程 200 mg沙利度胺或安慰剂口服每日一次。